Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
Nabil G. Seidah
Journal of Lipid Research (2021) Vol. 62, pp. 100130-100130
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K/AKT signaling in tumor cells and phenotypic polarization of macrophages
Lu Wang, Shuangshuang Li, Huanhua Luo, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 140
PCSK9 Inhibition: From Current Advances to Evolving Future
Chunping Liu, Jing Chen, Huiqi Chen, et al.
Cells (2022) Vol. 11, Iss. 19, pp. 2972-2972
Open Access | Times Cited: 62
Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
Iveta Merćep, Nikolina Friščić, Dominik Strikić, et al.
Cardiovascular Therapeutics (2022) Vol. 2022, pp. 1-6
Open Access | Times Cited: 61
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
Nabil G. Seidah, Damien Garçon
Current Atherosclerosis Reports (2022) Vol. 24, Iss. 10, pp. 821-830
Open Access | Times Cited: 55
PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
Vincenzo Quagliariello, Irma Bisceglia, Massimiliano Berretta, et al.
Cancers (2023) Vol. 15, Iss. 5, pp. 1397-1397
Open Access | Times Cited: 26
Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection
Khursheed Muzammil, Mohammad Hosseini Hooshiar, Shirin Varmazyar, et al.
Microbial Cell Factories (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 14
Harnessing RNA Interference for Cholesterol Lowering: The Bench‐to‐Bedside Story of Inclisiran
Michael J. Wilkinson, Archna Bajaj, Margaret E. Brousseau, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 6
Open Access | Times Cited: 13
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
Yan Gu, Xiaozeng Lin, Ying Dong, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 21
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Łukasz Wołowiec, Joanna Osiak, Anna Wołowiec, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 323-323
Open Access | Times Cited: 18
Functions and therapeutic interventions of non-coding RNAs associated with TLR signaling pathway in atherosclerosis
Ria Margiana, Fahad Alsaikhan, Ghaidaa Raheem Lateef Al‐Awsi, et al.
Cellular Signalling (2022) Vol. 100, pp. 110471-110471
Closed Access | Times Cited: 28
Chasing LDL cholesterol to the bottom — PCSK9 in perspective
Peter Libby, Lâle Tokgözoğlu
Nature Cardiovascular Research (2022) Vol. 1, Iss. 6, pp. 554-561
Open Access | Times Cited: 27
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Tafolecimab, a Third Monoclonal Antibody for PCSK9 as the Novel Lipid-Lowering Drug Around the World: A Narrative Review
Huihui Liu, Sha Li, Jian‐Jun Li
Drugs (2025)
Closed Access
Evolocumab attenuates myocardial ischemia/reperfusion injury by blocking PCSK9/LIAS-mediated cuproptosis of cardiomyocytes
Zeqian Li, Lei Guo, Yuqiu An, et al.
Basic Research in Cardiology (2025)
Closed Access
Saffron and its active constituents ameliorate hypercholesterolemia by inhibiting PCSK9 and modulating Sortilin, LDLR, and SREBP-2 signaling in high fat diet induced hypercholesterolemic C57BL/6 mice
Aisha Siddiq A, Shaik Abdul Dileep, S.J. Aditya Rao, et al.
Journal of Ethnopharmacology (2025), pp. 119697-119697
Closed Access
PCSK9 Promotes the Malignancy of Triple‐negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3
Tianhong Li, Renfei Wu, Kathy Qian Luo
Advanced Science (2025)
Open Access
Investigation of the interplay of PCSK9, cardiac dynamics, oxidative stress in coronary artery disease: case-control study
A. Lafta, Hamidreza Shiri, Mahsa Iraji, et al.
Frontiers in Endocrinology (2025) Vol. 16
Open Access
FURIN gene variants (rs6224/rs4702) as potential markers of death and cardiovascular traits in severe COVID‐19
Eliécer Coto, Guillermo M. Albaiceta, Laura Amado‐Rodríguez, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 8, pp. 3589-3595
Open Access | Times Cited: 13
An anti-PCSK9 pill a day to keep cholesterol away: next steps?
Gerald F. Watts
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 3, pp. 151-153
Closed Access | Times Cited: 2
Insights into PCSK9-LDLR Regulation and Trafficking via the Differential Functions of MHC-I Proteins HFE and HLA-C
Sepideh Mikaeeli, Ali Ben Djoudi Ouadda, Alexandra Evagelidis, et al.
Cells (2024) Vol. 13, Iss. 10, pp. 857-857
Open Access | Times Cited: 2
The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment
Gabriella Testa, Serena Giannelli, Erica Staurenghi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13637-13637
Open Access | Times Cited: 2
Improved split prime editors enable efficient in vivo genome editing
Rong Wei, Zhenxing Yu, Lihong Ding, et al.
Cell Reports (2024) Vol. 44, Iss. 1, pp. 115144-115144
Open Access | Times Cited: 2
PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function
Azin Kheirkhah, Claudia Lamina, Barbara Kollerits, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 6, pp. 809-818
Open Access | Times Cited: 11
PCSK9 inhibition interrupts the cross-talk between keratinocytes and macrophages and prevents UVB-induced skin damage
Chao Luan, Yingxue He, Wen Liu, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 7, pp. 104895-104895
Open Access | Times Cited: 6
The Immunogenic Potential of PCSK9 Peptide Vaccine in Mice
Sarina Ataei, Amir Abbas Momtazi‐Borojeni, Shiva Ganjali, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 26, pp. 3024-3031
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top